SG11202005216XA - Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof - Google Patents
Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereofInfo
- Publication number
- SG11202005216XA SG11202005216XA SG11202005216XA SG11202005216XA SG11202005216XA SG 11202005216X A SG11202005216X A SG 11202005216XA SG 11202005216X A SG11202005216X A SG 11202005216XA SG 11202005216X A SG11202005216X A SG 11202005216XA SG 11202005216X A SG11202005216X A SG 11202005216XA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- heterodimer
- preparation
- bispecific antibody
- natural
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711261880 | 2017-12-04 | ||
| PCT/CN2018/118800 WO2019109876A1 (zh) | 2017-12-04 | 2018-12-01 | 抗pd‐l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005216XA true SG11202005216XA (en) | 2020-07-29 |
Family
ID=66750763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005216XA SG11202005216XA (en) | 2017-12-04 | 2018-12-01 | Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11739151B2 (de) |
| EP (1) | EP3722322A4 (de) |
| JP (1) | JP7231641B2 (de) |
| KR (1) | KR20200093639A (de) |
| CN (1) | CN111615521A (de) |
| AU (1) | AU2018378529A1 (de) |
| BR (1) | BR112020011295A2 (de) |
| CA (1) | CA3084626A1 (de) |
| EA (1) | EA202091364A1 (de) |
| IL (1) | IL275135A (de) |
| MX (1) | MX2020005792A (de) |
| SG (1) | SG11202005216XA (de) |
| WO (1) | WO2019109876A1 (de) |
| ZA (1) | ZA202003382B (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3504234A4 (de) * | 2016-09-29 | 2020-12-02 | Beijing Hanmi Pharmaceutical Co., Ltd. | Heterodimere immunglobulinkonstrukte und herstellungsverfahren dafür |
| BR112019010051A2 (pt) | 2016-11-18 | 2019-09-03 | Beijing Hanmi Pharmaceutical Co Ltd | anticorpo biespecífico heterodimérico, polinucleotídeo isolado, vetor de expressão recombinante, célula hospedeira, composição, método de produzir o anticorpo biespecífico heterodimérico, uso do anticorpo bieífico heterodimérico, e método de prevenir e/ou tratar uma doença |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| CN115397853A (zh) * | 2019-12-17 | 2022-11-25 | 辉瑞大药厂 | 对cd47、pd-l1具特异性的抗体及其用途 |
| EP4112647A4 (de) * | 2020-02-28 | 2024-03-27 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-cd47/anti-pd-l1-antikörper und anwendungen davon |
| US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
| US10894812B1 (en) | 2020-09-30 | 2021-01-19 | Alpine Roads, Inc. | Recombinant milk proteins |
| AU2021353004A1 (en) | 2020-09-30 | 2023-04-13 | Nobell Foods, Inc. | Recombinant milk proteins and food compositions comprising the same |
| US20230365681A1 (en) * | 2020-10-07 | 2023-11-16 | Celgene Corporation | Bispecific antibody treatment of lymphoid malignant neoplasm conditions |
| JP2023551113A (ja) * | 2020-11-06 | 2023-12-07 | バイオ－テラ ソリュ－ションズ，エルティーディー． | 二重特異性抗体及びその応用 |
| WO2022100694A1 (zh) * | 2020-11-12 | 2022-05-19 | 迈威(上海)生物科技股份有限公司 | 抗体及其制备方法 |
| EP4276113A1 (de) * | 2021-01-08 | 2023-11-15 | Beijing Hanmi Pharmaceutical Co., Ltd. | Spezifisch an cd47 bindender antikörper und antigenbindendes fragment davon |
| WO2022148411A1 (zh) * | 2021-01-08 | 2022-07-14 | 北京韩美药品有限公司 | 抗pd-l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| CA3212599A1 (en) * | 2021-03-22 | 2022-09-29 | Novimmune S.A. | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
| AU2022270543A1 (en) * | 2021-05-07 | 2023-11-30 | Immuneoncia Therapeutics, Inc. | Bispecific antibody specifically binding to cd47 and pd-l1 |
| CN115702931A (zh) * | 2021-08-06 | 2023-02-17 | 百奥泰生物制药股份有限公司 | 抗pd-l1/cd47双特异抗体在治疗疾病中的应用 |
| CA3239434A1 (en) * | 2022-01-18 | 2023-07-27 | Fbd Biologics Limited | Cd47/pd-l1-targeting protein complex and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| AU2011325833C1 (en) * | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| SI2838918T1 (sl) * | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za proizvodnjo heterodimernih IG-podobnih molekul |
| ES2784631T3 (es) | 2012-12-03 | 2020-09-29 | Novimmune Sa | Anticuerpos anti-CD47 y métodos de uso de los mismos |
| WO2016023001A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| LT3180363T (lt) | 2014-08-15 | 2019-11-25 | Merck Patent Gmbh | Sirp-alfa imunoglobulino sulieti baltymai |
| EA037654B1 (ru) | 2014-12-30 | 2021-04-27 | Селджин Корпорейшн | Анти-cd47-антитела и их применения |
| SI3331902T1 (sl) | 2015-08-07 | 2021-09-30 | ALX Oncology Inc. | Konstrukti z domeno SIRP-alfa ali njegove različice |
| EP3349787A4 (de) * | 2015-09-18 | 2019-03-27 | Arch Oncology, Inc. | Therapeutische cd47-antikörper |
| CN106883297B (zh) * | 2015-12-16 | 2019-12-13 | 苏州康宁杰瑞生物科技有限公司 | 基于ch3结构域的异二聚体分子、其制备方法及用途 |
| WO2017167350A1 (en) | 2016-03-30 | 2017-10-05 | Horst Lindhofer | Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract |
| EP3504234A4 (de) * | 2016-09-29 | 2020-12-02 | Beijing Hanmi Pharmaceutical Co., Ltd. | Heterodimere immunglobulinkonstrukte und herstellungsverfahren dafür |
| BR112019010051A2 (pt) * | 2016-11-18 | 2019-09-03 | Beijing Hanmi Pharmaceutical Co Ltd | anticorpo biespecífico heterodimérico, polinucleotídeo isolado, vetor de expressão recombinante, célula hospedeira, composição, método de produzir o anticorpo biespecífico heterodimérico, uso do anticorpo bieífico heterodimérico, e método de prevenir e/ou tratar uma doença |
| WO2019047885A1 (en) * | 2017-09-07 | 2019-03-14 | Dingfu Biotarget Co., Ltd. | IMMUNOCONJUGATES COMPRISING ALPHA REGULATORY SIGNAL PROTEIN |
| EA039662B1 (ru) | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
| US20200354458A1 (en) | 2017-11-20 | 2020-11-12 | Taizhou Mabtech Pharmaceutical Co., Ltd. | Bifunctional Fusion Protein Targeting CD47 and PD-L1 |
| EP4112647A4 (de) * | 2020-02-28 | 2024-03-27 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-cd47/anti-pd-l1-antikörper und anwendungen davon |
-
2018
- 2018-12-01 BR BR112020011295-0A patent/BR112020011295A2/pt not_active IP Right Cessation
- 2018-12-01 WO PCT/CN2018/118800 patent/WO2019109876A1/zh unknown
- 2018-12-01 JP JP2020549852A patent/JP7231641B2/ja active Active
- 2018-12-01 EP EP18887151.1A patent/EP3722322A4/de active Pending
- 2018-12-01 AU AU2018378529A patent/AU2018378529A1/en not_active Abandoned
- 2018-12-01 KR KR1020207019202A patent/KR20200093639A/ko unknown
- 2018-12-01 CA CA3084626A patent/CA3084626A1/en active Pending
- 2018-12-01 US US16/769,108 patent/US11739151B2/en active Active
- 2018-12-01 MX MX2020005792A patent/MX2020005792A/es unknown
- 2018-12-01 EA EA202091364A patent/EA202091364A1/ru unknown
- 2018-12-01 SG SG11202005216XA patent/SG11202005216XA/en unknown
- 2018-12-01 CN CN201880070773.3A patent/CN111615521A/zh active Pending
-
2020
- 2020-06-04 IL IL275135A patent/IL275135A/en unknown
- 2020-06-05 ZA ZA2020/03382A patent/ZA202003382B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7231641B2 (ja) | 2023-03-01 |
| JP2021505195A (ja) | 2021-02-18 |
| EA202091364A1 (ru) | 2020-10-13 |
| MX2020005792A (es) | 2020-11-06 |
| IL275135A (en) | 2020-07-30 |
| AU2018378529A1 (en) | 2020-06-18 |
| US20210230277A1 (en) | 2021-07-29 |
| BR112020011295A2 (pt) | 2020-11-24 |
| US11739151B2 (en) | 2023-08-29 |
| KR20200093639A (ko) | 2020-08-05 |
| WO2019109876A1 (zh) | 2019-06-13 |
| EP3722322A1 (de) | 2020-10-14 |
| EP3722322A4 (de) | 2021-09-15 |
| CA3084626A1 (en) | 2019-06-13 |
| ZA202003382B (en) | 2021-06-30 |
| CN111615521A (zh) | 2020-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202003382B (en) | Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof | |
| IL279053A (en) | Bispecific anti-PVRIG/ anti-TIGIT antibodies and methods of use | |
| HK1258304A1 (zh) | 優化抗cd3雙特異性抗體和其用途 | |
| HK1252857A1 (zh) | 抗cd3抗體及其使用方法 | |
| HK1259426A1 (zh) | Pd-l1抗體及其用途 | |
| HK1255604A1 (zh) | 抗pd-l1抗體及其用途 | |
| SG11202002530RA (en) | Anti-pd-l1 antibody and uses thereof | |
| HK1257840A1 (zh) | 抗-pd-1抗體及其使用方法 | |
| HK1252158A1 (zh) | 掩蔽抗cd3抗體和使用方法 | |
| ZA201902533B (en) | Anti-pd-l1 antibodies and variants | |
| RS64576B1 (sr) | Anti-tigit antitela i postupci njihove primene | |
| RS64419B1 (sr) | Anti-trem2 antitela i postupci za njihovu upotrebu | |
| ZA201906457B (en) | Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof | |
| IL268112A (en) | Anti-TGF-beta antibodies and their use | |
| IL251128A0 (en) | Bispecific antibodies and methods of use in ophthalmology | |
| IL275734B (en) | Anti-pd-l1 antibodies and uses thereof | |
| IL268051A (en) | Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof | |
| SG10201913260VA (en) | Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same | |
| IL273484A (en) | A33 antibody preparations and methods for their use in radioimmunotherapy | |
| IL275492A (en) | Construct of a bispecific antibody directed against MUC17 and CD3 | |
| EP3534951A4 (de) | Anti-cd40-antikörper in kombination und verfahren zur verwendung | |
| SG11202003980PA (en) | Anti-apoc3 antibodies and methods of use thereof | |
| IL271346A (en) | Bispecific antibodies and methods for their preparation and use | |
| IL273538A (en) | Anti-TRKB Monoclonal Antibodies and Methods of Use | |
| ZA201906513B (en) | Anti-pd-l1 antibody and use thereof |